In July, Cynata received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a patent application covering the use of its Cymerus™ MSCs in treating asthma and allergic airways disease. The patent adds yet another string to the Company’s bow which now has multiple applications under investigation for its off-the-shelf stem cell product.
A study conducted by Professor Chrishan Samuel, a Monash Biomedicine Discovery Fellow and Head of the Fibrosis Laboratory, Department of Pharmacology at Monash University, found that in an animal model of idiopathic pulmonary fibrosis (IPF), Cynata’s stem cells ameliorated the mediators of lung inflammation while at the same time promoting anti-inflammatory effects. Why is this exciting?
An avid surfer of over 50 years, Ross has a vested interest in helping us live better for longer, especially protecting our joints. In early June he spoke with the Australian Financial Review about his love of surfing, and how he finds peace of mind and strategic clarity while riding waves
Managing Director Dr Ross Macdonald spoke to Matt Birney on the Bulls N’ Bears Report about the FDA clearing Cynata’sInvestigational New Drug (IND) application for a Phase 2 acute graft versus host disease (aGvHD) trial adding yet another indication to Cynata's broad and robust clinical pipeline.
In exciting news, the US FDA cleared Cynata’s Investigational New Drug (IND) application for a Phase 2 clinical trial of CYP-001 in patients with acute graft versus host disease (aGvHD). The planned Phase 2 clinical trial will seek to recruit approximately 60 patients with high risk aGvHD, at clinical centres in several countries, including the US and Australia. FDA clearance is a major achievement and valuation milestone for the Company.
The stock was up 10 per cent following the announcement, read the full details on The Australian: